TY - JOUR
T1 - Role of temozolomide in the treatment of cancers involving the central nervous system
AU - Schreck, Karisa C.
AU - Grossman, Stuart A.
N1 - Publisher Copyright:
© 2018, UBM Medica Healthcare Publications. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Temozolomide has been available to oncologists for over 30 years. During this time, it has become an integral part of standard therapy in patients with high-grade gliomas. Given its ability to traverse the blood-brain barrier, temozolomide has also been evaluated in other cancers that involve the central nervous system (CNS). We review its role in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. There is strong evidence that temozolomide is effective in patients with high-grade astrocytomas and oligodendrogliomas. Modest evidence supports its activity in primary CNS lymphomas and aggressive pituitary adenomas. Temozolomide, however, has minimal efficacy in a wide variety of systemic cancers. Given that concentrations of temozolomide in the CNS are only 20% of those in the blood, it is not surprising that it is generally inactive in patients with CNS metastases from solid tumors.
AB - Temozolomide has been available to oncologists for over 30 years. During this time, it has become an integral part of standard therapy in patients with high-grade gliomas. Given its ability to traverse the blood-brain barrier, temozolomide has also been evaluated in other cancers that involve the central nervous system (CNS). We review its role in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. There is strong evidence that temozolomide is effective in patients with high-grade astrocytomas and oligodendrogliomas. Modest evidence supports its activity in primary CNS lymphomas and aggressive pituitary adenomas. Temozolomide, however, has minimal efficacy in a wide variety of systemic cancers. Given that concentrations of temozolomide in the CNS are only 20% of those in the blood, it is not surprising that it is generally inactive in patients with CNS metastases from solid tumors.
UR - http://www.scopus.com/inward/record.url?scp=85057097534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057097534&partnerID=8YFLogxK
M3 - Review article
C2 - 30474103
AN - SCOPUS:85057097534
SN - 0890-9091
VL - 32
SP - 555-560, 569
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 11
ER -